First-line Axitinib plus Pembrolizumab in advanced renal cell carcinoma: retrospective real world data from a multicentre patient cohort

被引：0
|
作者：
Darr, Christopher [1 ,2 ]
Stelmach, Ramona [3 ]
Schlack, Katrin [4 ]
Dinkel, Hendrik [4 ]
Paffenholz, Pia [5 ,6 ]
Ivanyi, Philipp [7 ]
Wiegmann, Jonas [7 ]
Schulz, Anton
Kramer, Mario
Schnabel, Marco [8 ]
Rinderknecht, Emily [8 ]
Handke, Analena [9 ]
Hilser, Thomas
Heidenreich, Axel
Hadaschik, Boris [1 ,2 ,5 ,6 ]
Zschaebitz, Stefanie [3 ]
Gruenwald, Viktor [1 ,2 ,10 ]
机构：
[1] Univ Hosp Essen & German Canc Consortium DKTK, Dept Urol, Essen, Germany
[2] German Canc Consortium DKTK, Essen, Germany
[3] Heidelberg Univ Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany
[4] Univ Hosp Muenster, Dept Urol, Munster, Germany
[5] Univ Cologne, Fac Med, Dept Urol Urooncol, Robot Assisted & Reconstruct Urol Surg, Cologne, Germany
[6] Univ Hosp Cologne, Cologne, Germany
[7] Dept Hematol Hemostasis Oncol & Stem Cell, Lubeck, Germany
[8] Univ Hosp Regensburg, Dept Urol, Regensburg, Germany
[9] Ruhr Univ Bochum, Marienhospital Herne, Dept Urol, Herne, Germany
[10] Univ Hosp Essen, Dept Oncol, Essen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
55
引用
收藏
页码：79 / 80
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
    Plimack, Elizabeth R.
    Rini, Brian, I
    Stus, Viktor
    Gafanov, Rustem
    Waddell, Tom
    Nosov, Dmitry
    Pouliot, Frederic
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    McDermott, Raymond S.
    Bedke, Jens
    Tamada, Satoshi
    Yin, Lina
    Chen, Mei
    Molife, L. Rhoda
    Atkins, Michael B.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] KEYNOTE-426 Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
    Bedke, J.
    Stuehler, V.
    UROLOGE, 2020, 59 (07): : 841 - 842
  • [23] Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry
    Uhlig, Annemarie
    Uhlig, Johannes
    Woike, Michael
    Fischer, Thomas
    Trojan, Lutz
    Bergmann, Lothar
    Goebell, Peter J.
    Rink, Michael
    Schlack, Katrin
    Leitsmann, Marianne
    Strauss, Arne
    KIDNEY CANCER, 2023, 7 (01) : 37 - 48
  • [24] Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/metastatic renal cell carcinoma
    Wang, Yufei
    Zhong, Yichen
    Mt-Isa, Shahrul
    Perini, Rodolfo
    Adejoro, Oluwakayode
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [25] Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART)
    Kato, Taigo
    Nakano, Yuzo
    Hongo, Fumiya
    Katano, Hidenori
    Miyagawa, Tomoaki
    Ueda, Kosuke
    Azuma, Haruhito
    Nozawa, Masahiro
    Hinata, Nobuyuki
    Hori, Junichi
    Otoshi, Taiyo
    Shimizu, Nobuaki
    Aizawa, Mana
    Osada, Shingo
    Matsui, Akiko
    Oya, Mototsugu
    Eto, Masatoshi
    Tomita, Yoshihiko
    Shinohara, Nobuo
    Uemura, Hirotsugu
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (03) : 265 - 272
  • [26] KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
  • [27] COST-EFFECTIVENESS OF PEMBROLIZUMAB plus AXITINIB VERSUS NIVOLUMAB plus IPILIMUMAB AS FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL
    Garmatter, L. P. Leonart
    Berlinski, F.
    Rego, M. A. D. C.
    Bastos, D. A.
    Soares, A.
    Kater, F. R.
    Nunes, A. A.
    Santos, M.
    Riveros, B. Salgado
    VALUE IN HEALTH, 2023, 26 (06) : S149 - S150
  • [28] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Hawkins, Robert
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    Szczylik, Cezary
    Markus, Maurice
    McDermott, Raymond S.
    Bedke, Jens
    Tartas, Sophie
    Chang, Yen-Hwa
    Tamada, Satoshi
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
  • [29] Initial clinical experience of pembrolizumab plus axitinib for advanced renal cell carcinoma
    Ieda, Takeshi
    Anno, Yuta
    Kurosawa, Makoto
    Kure, Akimasa
    Koyasu, Hiroki
    Takahata, Sohei
    Hino, Amiko
    Kitamura, Kosuke
    Nagata, Masayoshi
    Wakumoto, Yoshiaki
    Sakamoto, Yoshiro
    Tsujimura, Akira
    Horie, Shigeo
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 6 - 7
  • [30] Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination
    Aydogdu, C.
    Paffenholz, P.
    Stelmach, R.
    Schlack, K.
    Roghmann, F.
    Handke, A.
    Mandal, S.
    Schnabel, M.
    Merseburger, A.
    Ivanyi, P.
    Tschaebitz, S.
    Darr, C.
    Gruenwald, V.
    Stief, C. G.
    Casuscelli, J.
    EUROPEAN UROLOGY, 2024, 85 : S1858 - S1858
12345